Mesco Pharmaceuticals Peer Comparison

NSE: MESCOPHARM | BSE: 500274

₹4.54

₹0.21 (4.85%)

As on 10-Jan-2022IST

Market cap

₹9 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

P/B Ratio

-0.9

Div. Yield

0 %

Edit

	Mesco Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	9	35,504	27,675	26,306	27,978
Revenue (₹ Cr)	--	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	-0.01	414.00	288.22	387.35	-371.81
Net Margin (%)	--	11.23	14.79	26.01	-3.93
RoE (%)	--	8.38	29.77	25.18	-3.85
Price to Earnings	--	86.81	96.02	68.11	--
Price-To-Book	-0.88	7.05	20.62	15.25	3.50

Income Statement (₹ Cr)

	Mesco Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	--	2,708.00	314.72	340.61	6,314.90
Total Income	0.00	2,840.00	324.85	341.99	6,479.01
Total Expenditure	0.00	2,771.00	223.05	260.45	4,886.94
EBITDA	0.00	-63.00	91.67	80.15	1,427.96
Depreciation	--	246.00	29.31	4.19	545.04
EBIT	0.00	-309.00	62.36	75.96	882.92
Interest	0.00	249.00	9.37	5.62	163.45
Other Income	--	132.00	10.13	1.38	164.11
Exceptional Items	--	-142.00	--	--	18.23
Profit before Tax	0.00	-568.00	63.12	71.73	949.05
Provision for Tax	--	-271.00	32.43	17.73	114.02
Profit after Tax	0.00	-297.00	30.69	54.00	835.03

	Mesco Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	-11.02	3,376.00	374.15	166.93	5,605.00
Minority Interest	--	383.00	0.00	--	--
Non-Current Liabilities	11.18	496.00	52.94	80.29	2,560.38
Current Liabilities	0.02	3,121.00	111.16	166.04	2,590.70
Total Liabilities	0.18	7,746.00	538.25	413.27	10,777.71

	Mesco Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	0.18	4,951.00	201.99	190.83	7,006.96
Current Assets	0.00	2,281.00	336.26	216.23	3,749.12
Total Assets	0.18	7,746.00	538.25	413.27	10,777.71
Total Debt*	11.18	2,332.00	93.28	136.64	2,910.19
Net Current Assets	-0.01	-840.00	225.10	50.19	1,158.42
Contingent Liabilities	--	639.00	30.36	0.00	29.98

	Mesco Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	0.00	-287.00	56.87	27.96	597.58
Cash Flow from Investing Activities	--	1,470.00	-36.45	-101.21	-4,479.93
Cash from Financing Activities	-0.03	-1,171.00	52.49	72.11	3,976.83
Net Cash Inflow / Outflow	-0.04	12.00	72.91	-1.14	94.48

	Mesco Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	-2.08	-5.50	17.30	33.43	13.06
ROE (%)	0.00	-9.92	8.84	40.51	14.90
ROA (%)	-1.99	-3.93	6.36	16.74	7.76
EBIT Margin (%)	--	2.55	32.35	23.94	25.21
Net Margin (%)	--	-10.46	9.45	15.79	12.89
Cash Profit Margin (%)	--	-1.10	19.06	17.08	19.71

	Mesco Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	--	-4.78	19.65	42.13	0.00
EBIT Growth (%)	96.07	-56.28	3.17	85.90	--
Net Profit Growth (%)	95.93	-115.30	-37.89	96.57	0.00
EPS Growth (%)	95.98	1,097.71	-37.89	-34.47	0.00
Book Value Growth (%)	-0.04	26.74	8.89	51.79	0.00

	Mesco Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	0.00	6.12	0.00	0.00	0.00
Price / Book Value	0.00	1.36	0.00	0.00	0.00
Dividend Yield (%)	--	0.00	--	--	--
EV/EBITDA	-7,999.21	95.62	0.14	2.03	2.20
Market Cap (₹ Cr)	--	4,557.85	0.00	0.00	0.00

	Mesco Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	-1.02	0.70	0.26	0.85	0.52
Short term debt to equity ratio	--	0.32	0.12	0.27	0.06
Current Ratio	0.18	0.73	3.02	1.30	1.45
Quick Ratio	0.18	0.47	2.46	0.94	0.97
Interest Coverage	-28.38	-1.28	7.74	13.77	6.81

	Mesco Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	--	33.90	43.28	35.43	24.94
Asset Turnover	0.00	0.61	0.65	1.06	0.65
Receivable days	--	85.04	160.21	94.89	82.08
Inventory Days	--	59.63	58.00	60.39	64.21
Payable days	--	255.87	183.24	138.36	162.72
Cash Conversion Cycle	--	-111.19	34.97	16.92	-16.42

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.